Our Pipeline

Differentiated pipeline based on transformative innovations

Our rich pipeline has the potential to shift ophthalmic treatment paradigms and make a real difference in patients’ lives

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

OCS-05

Other Candidates

PRODUCT CANDIDATE

OCS-01

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Other Retinal Edema

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

OCS-02

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

OCS-05

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Neuro-Ophthalmic Disorders

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Other Candidates

Retinal Disorders

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

Ocular Inflammation

Product Candidate

Investigational indication

Preclinical

Phase 1

Phase 2

Phase 3

OCS-01, OCS-02 and OCS-05 are investigational drugs and have not received regulatory approval for commercial use in any country.

Our Potential to Transform Eye Care and Improve Patient Outcomes

Rethinking Ophthalmology to Save Sight and Improve Eye Care

We are rethinking ophthalmology by building and constantly advancing our innovative and differentiated pipeline which has the potential to transform eye care and improve vision for patients around the world.”

Rethinking Ophthalmology